Search Results - "Maris, M.B."

Incidence of Hyperglycemia in Acute Allogeneic Hematopoietic Stem Cell Transplant by Schlatter, M, Gregory, T.K, Panter, E, Maris, M.B, McSweeney, P

Get full text

TREATMENT OF RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA (NHL) WITH LISOCABTAGENE MARALEUCEL IN THE OUTPATIENT SETTING: RESULTS FROM TWO PHASE 2 TRIALS by Sehgal, A., Godwin, J.E., Maris, M.B., Hildebrandt, G.C., Trede, N.S., Kostic, A., Wang, L., Lymp, J., Bachier, C.R.

Get full text

368: Longer follow up of patients (pts) with advanced chronic lymphocytic leukemia (CLL) treated with nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) by Sorror, M.L, Storer, B, Sandmaier, B.M, Maris, M.B, Shizuru, J, Niederwieser, D, Agura, E, Chauncey, T, Maziarz, R, Pulsipher, M, McSweeney, P, Wade, J, Bruno, B, Langston, A, Blume, K, Storb, R, Maloney, D.G

Get full text

Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning by Sandmaier, Brenda M., Maris, M.B., Maloney, D.G., Gooley, T.A., Shizuru, J.A., Niederwieser, D.W., Chauncey, T.R., Sahebi, F., Agura, E., Maziarz, R.T., Bruno, B., Pulsipher, M., Langston, A.A., Wade, J., McSweeney, P.A., Epner, E., Bethge, W., Forman, S.J., Blume, K.G., Storb, R.

“…Nonmyeloablative conditioning regimens for allogeneic HCT were introduced to reduce the non-relapse mortality and as a therapeutic modality to patients (pts)…”
Get full text

Feasibility and Toxicity of Nonmyeloablative Hematopoietic Cell Transplantation (HCT) with or without Imatinib for Philadelphia Chromosome (Ph+) Acute Lymphoblastic Leukemia (ALL) by Norasetthada, L., Maris, M.B., Sandmaier, B.M., Maloney, D.G., Georges, G., Druker, B., Radich, J., Storb, R.

“…Background: Ph+ is a risk factor for adult ALL and represents an indication for conventional allogeneic HCT. Purpose: To determine whether safety and efficacy…”
Get full text

HLA-Matched Related (MRD) or Unrelated Donor (URD) Non-Myeloablative Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Refractory and Relapsed Aggressive Non Hodgkin Lymphoma (NHL) by Norasetthada, L., Maris, M.B., Sandmaier, B.M., Gooley, T., Forman, S., Agura, E., Maziarz, R.T., Shizuru, J., Niederwieser, D., Storb, R., Maloney, D.G.

“…There are few treatment options for pts with relapsed aggressive T and B cell NHL after failure of auto HCT and subsequent high dose allo HCT has resulted in…”
Get full text

Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT by Sorror, M.L., Maris, M.B., Storb, R.F., Baron, F., Sandmaier, B.M., Maloney, D.G., Barry, S.E.

Get full text

Nonmyeloablative unrelated donor (URD) hematopoietic cell transplantation (HCT) for the treatment of patients (PTS) with poor-risk, relapsed or refractory multiple myeloma by Georges, G.E., Maris, M.B., Maloney, D.G., Sandmaier, B.M., Sorror, M.L., Shizuru, J.A., Niederwieser, D.W., Agura, E.D., Bruno, B., McSweeney, P.A., Pulsipher, M.A., Chauncey, T.R., Storer, B.E., Storb, R.F.

Get full text

Unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with poor risk, relapsed or refractory multiple myeloma by Georges, G.E., Maris, M.B., Sandmaier, B.M., Stuart, M.J., Niederwieser, D., Agura, E., Bruno, B., McSweeney, P., Anasetti, C., Storb, R., Maloney, D.G.

Get full text

TID compared to BID mycophenolate mofetil (MMF) improves donor chimerism and engraftment rates without increasing postgrafting toxicities after unrelated peripheral blood stem cell (PBSC) transplantation (HCT) with nonmyeloablative conditioning by Maris, M.B., Sandmaier, B.M., Storer, B., Stuart, M., Agura, E., Hegenbart, U., Pulsipher, M., Maziarz, R.T., Bruno, B., McSweeney, P., Maloney, D., Niederwieser, D., Blume, K., Storb, R.

Get full text

Treatment for acute myelogenous leukemia by low dose Total Body Irradiation (TBI) based conditioning and hematopoietic cell transplantation from related and unrelated donors by Franke, G.N., Hegenbart, U., Niederwieser, D., Sandmaier, B.M., Maris, M.B., Shizuru, J.A., Stuart, M., Greinix, H., Cordonnier, C., Rio, B., Gratwohl, A., Lange, T., Poenisch, W., Grommisch, L., Al-Ali, H., Storer, B., Maloney, D., Petersdorf, E., McSweeney, P., Chauncey, T., Agura, E., Epner, E., Maziarz, R.T., Petersen, F., Bruno, B., Storb, R.

Get full text

HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD) by Burroughs, L.M., Maris, M.B., Sandmaier, B.M., Leisenring, W., Jain Stuart, M., Niederwieser, D., McSweeney, P.A., Chauncey, T., Maziarz, R., Agura, E., Little, M.-T., Blume, K.G., Storb, R., Maloney, D.G.

Get full text

Treatment of patients (pts) with chemotherapy-refractory chronic lymphocytic leukemia (CLL) with nonmyeloablative (NM) conditioning and hematopoietic cell transplantation (HCT) from HLA-matched related (MRD) or unrelated donors (URD) by Sorror, M.L., Maris, M.B., Sandmaier, B.M., Jain-Stuart, M., Storer, B., Hegenbart, U., McSweeney, P., Chauncey, T., Bruno, B., Wade, J., Agura, E., Pulsipher, M., Leis, J., Little, M.-T., Niederwieser, D., Blume, K., Storb, R., Maloney, D.G.

Get full text

Factors contributing to difference in performance between small and large sections by Maris, J.-M.B., Jacobs, E.L.

“…Using large sections is a common option for extending scarce faculty resources. However, the students in small sections of an introductory course in computer…”
Get full text